Optimizing Rexulti Denial Management with Klivira Automation
Rexulti denial management presents unique challenges for revenue cycle teams, driven by complex formulary requirements and clinical necessity reviews. Klivira automates the entire denial workflow to accelerate appeals and improve overturn rates.
As a high-volume prior authorization target across commercial, Medicare Advantage, and Medicaid managed care plans, Rexulti frequently encounters denials related to formulary compliance, step therapy, and medical necessity. Manually managing these appeals consumes significant staff resources and risks timely filing breaches, directly impacting revenue realization. Klivira provides a robust solution to these operational inefficiencies.
The Specifics of Rexulti Prior Authorization Denials
Denials for atypical antipsychotics like Rexulti often stem from payer-specific formulary requirements, step-therapy protocols, or insufficient clinical documentation supporting medical necessity. These denials can arrive via X12 835 for billed services or X12 277 for pre-service PA denials, necessitating precise parsing of CARC and RARC codes or portal-specific denial text to determine the correct appeal pathway.
Common Rexulti Denial Triggers Addressed by Automation
- **Step Therapy Not Met:** Patient has not tried and failed required first-line therapies.
- **Lack of Medical Necessity:** Insufficient clinical justification for Rexulti over alternatives.
- **Formulary Non-Compliance:** Drug not on payer's formulary or requires a non-preferred status exception.
- **Documentation Gaps:** Missing psychiatric evaluations, symptom severity scales, or prior treatment history.
- **Timely Filing Breaches:** Appeals not submitted within payer-mandated windows.
Klivira's Automated Approach to Rexulti Denial Management
Klivira ingests Rexulti-related denials from all channels, including X12 835, X12 277, Da Vinci PAS `ClaimResponse`, and payer portal status events. Our system normalizes X12 CARC/RARC codes and payer-specific local variations into a uniform reason set, ensuring accurate categorization and routing to the appropriate appeal workflow (claim correction, appeal, or peer-to-peer review).
Streamlining Rexulti Appeal Packet Assembly and Submission
For clinical-necessity denials, Klivira automates the assembly of appeal packets by pulling relevant clinical documentation from the EMR via FHIR. This includes psychiatric evaluations, symptom severity scales (e.g., PANSS, CGI-S), prior line therapy attestations, and any notes added since the original PA submission. Appeals are then submitted via the payer's accepted channel, with timely-filing windows proactively enforced.
Actionable Insights for Future Rexulti Prior Authorizations
Beyond individual appeal management, Klivira's platform surfaces aggregated denial-reason patterns by payer and service line for Rexulti. This data provides critical feedback to your upstream prior authorization submission processes, enabling proactive adjustments to documentation and submission strategies to reduce future denials for similar high-volume medications.
Frequently asked questions
How does Klivira handle Rexulti step-therapy denials?
Klivira's system identifies step-therapy denials through automated CARC/RARC parsing and payer-specific logic. It then facilitates the appeal process by identifying and pulling documentation from the EMR via FHIR that attests to prior treatment failures or contraindications, assembling it into a comprehensive appeal packet for submission to the payer.
What EMR documentation does Klivira use for Rexulti appeals?
For Rexulti appeals, Klivira leverages FHIR to retrieve essential clinical documentation from the EMR. This typically includes psychiatric evaluations, progress notes detailing symptom severity, relevant lab results, and attestations of prior line therapy failures, ensuring the appeal packet is robust and payer-compliant.
Can Klivira track timely filing for Rexulti appeals across all payers?
Yes, Klivira's platform enforces per-payer timely-filing windows for Rexulti appeals. It proactively surfaces deadlines and tracks appeal status from submission through outcome, with auto-escalation features to prevent appeals from being lost to follow-up due to missed deadlines.
How does Klivira help identify root causes for recurring Rexulti denials?
Klivira's reporting and pattern detection capabilities analyze denial reasons for Rexulti across payers and providers. This allows your team to identify recurring issues, such as specific documentation gaps or formulary challenges, providing actionable intelligence to refine your upstream PA submission processes and reduce future denial rates.
Does Klivira automate peer-to-peer scheduling for Rexulti denials?
For high-acuity Rexulti denials requiring peer-to-peer review, Klivira routes scheduling requests to ordering clinicians and tracks the scheduling status. While Klivira streamlines the coordination, the actual peer-to-peer discussion requires clinician participation.
Related coverage
Ready to automate this workflow?
See how Klivira automates prior authorizations for your team.
Request a demo